{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-067791","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.745435+00:00","generated_at":"2026-05-18T01:11:29.010312+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"INmune Bio Phase 2 XPro trial misses primary endpoint; positive subpopulation data at AAIC","bullets":["Primary endpoint not met in mITT group; 208 early-AD participants with inflammation biomarkers.","Consistent benefit seen in subpopulation with Aβ pathology and ≥2 inflammatory biomarkers.","Oral presentation at AAIC on July 29, 2025 at 2:00-3:30 PM ET in Toronto.","Company seeking strategic partnership to accelerate XPro development for Alzheimer's.","Publication of full results anticipated by mid-August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-067791","json":"https://secwatch.observer/filing/0001213900-25-067791.json","markdown":"https://secwatch.observer/filing/0001213900-25-067791.md","text":"https://secwatch.observer/filing/0001213900-25-067791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025067791/0001213900-25-067791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025067791/ea0250327-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:11:29.010312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}